Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Possible biomarkers modulating haloperidol efficacy and/or tolerability.

Pharmacogenomics - 1 Apr 2016

Porcelli Stefano, Crisafulli Concetta, Calabrò Marco, Serretti Alessandro, Rujescu Dan

Abstract excerpt

Haloperidol (HP) is widely used in the treatment of several forms of psychosis. Despite of its efficacy, HP use is a cause of concern for the elevated risk of adverse drug reactions. adverse drug reactions risk and HP efficacy greatly vary across subjects, indicating the involvement of several factors in HP mechanism of action. The use of biomarkers that could monitor or even predict HP treatment impact would be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Biomarkers
Share to Epigenesis, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Profiling

Share to Genetic Markers

Share to Haloperidol

Share to Organ Specificity

Share to Psychotic Disorders

Source

Identifiers

PMID: 27023437
DOI: 10.2217/pgs.16.5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Possible biomarkers modulating haloperidol efficacy and/or tolerability.PMID 27023437Read ↗

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.Semantic proximity Read ↗

Personalizing Treatment for Acute Alcoholic Hallucinosis: Clinical Utility of Integrated Pharmacogenetic Testing, Metabolic Phenotyping, and microRNA Biomarkers.Semantic proximity Read ↗

Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.Semantic proximity Read ↗

Evidence-based umbrella review of 162 peripheral biomarkers for major mental disordersSemantic proximity Read ↗

The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.Semantic proximity Read ↗

Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment.Semantic proximity Read ↗

Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers.Semantic proximity Read ↗

Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.Semantic proximity Read ↗

Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses.Semantic proximity Read ↗

KarXT Combines the Partial Benefits of Haloperidol for Positive Symptoms and Sulpiride for Negative Symptoms: Evidence from Computational BiologySemantic proximity Read ↗

Behavioural effects of chronic haloperidol and risperidone treatment in rats.Semantic proximity Read ↗

Association of CYP2D6*4 Polymorphism with the Steady-State Concentration of Haloperidol in Patients with Alcohol-Induced Psychotic Disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.